Indoco Remedies
Indoco Remedies Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13). The company aims to return to EBITDA margins of around 11%-13% (levels seen pre-remediation issues), with quarter-on-quarter improvement expected.
From Indoco Remedies's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13).
- European sales are anticipated to bounce back to regular levels by Q3 FY '26 after overcoming supply challenges (Page 8).
- Domestic business showed 10% growth in IQVIA secondary sales with healthy double-digit growth in key segments; expectations are stable or improving (Page 9).
- OTC business grew over 46% sequentially and is expected to break even in a couple of years with enhanced marketing investments (Page 12).
- Semi-regulated markets show good growth driven by brand-building and revamped sales strategy, expected to sustain (Page 8).
2 more points from Indoco Remedies's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indoco Remedies said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX is being controlled carefully as per management.
- Ongoing projects at Goa Plant-2 and the API site for Warren Remedies are underway.
- Gradual completion of these projects is expected, but not entirely within this year.
2 more points from Indoco Remedies's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indoco Remedies said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As per the transcript, Indoco Remedies is currently ramping up manufacturing activities after receiving US FDA approval to restart two lines; however, sales from these sterile products are yet to happen.
- Full efficiency and rollout of plants, especially post-remediation, are expected by end of Q2 FY '26, with all plants fully operational by Q3 FY '26.
- The balancing of products and the right number of orders are still being established following last year’s supply disturbances.
- Europe supply challenges are expected to be overcome by end of Q2 FY '26, with a bounce back in Q3.
2 more points from Indoco Remedies's call on order book
Pro opens every point from 15K+ earnings calls
Indoco Remedies — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net loss ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indoco Remedies Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Fermenta Biotech Ltd (Q1 FY26)
Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) . Key concall takeaways from Fermenta Biotech Ltd's Q1 FY26 earnings call — and how it ranks…
- Amrutanjan Health Care Ltd (Q1 FY26)
94.05 Cr, up 12.31% from Rs. Key concall takeaways from Amrutanjan Health Care Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q1 FY26)
INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia). Key concall takeaways from Sigachi Industries Ltd's…
Arthneeti Pro · Annual
Indoco Remedies and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indoco Remedies Q1 FY26 results?
The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13). The company aims to return to EBITDA margins of around 11%-13% (levels seen pre-remediation issues), with quarter-on-quarter improvement expected.
What is Indoco Remedies share price analysis?
Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies planning capital expenditure?
Current CAPEX is being controlled carefully as per management. - Ongoing projects at Goa Plant-2 and the API site for Warren Remedies are underway. - Gradual completion of these projects is expected, but not entirely within this year. - Incremental CAPEX for the current year is not expected to exceed around Rs.
Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.